TrialBritish journal of cancer2023

Long-term, continuous infusion of single-agent dinutuximab beta for relapsed/refractory neuroblastoma: an open-label, single-arm, Phase 2 study.

Holger N Lode et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.